A Phase 4 interventional study of Ganeden BC30 and Placebo (sugar pill) in Major Depressive Disorder and Irritable Bowel Syndrome, sponsored by Massachusetts General Hospital. Terminated at 2 sites in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2013-08-09.
Sponsored by Massachusetts General Hospital · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 88 studies in Depressive Disorder, Major by Massachusetts General Hospital — 9 open to participants now, 12 under way, none of them phase 3. Depressive Disorder, Major · Massachusetts General Hospital.
Among the 88 studies in Depressive Disorder, Major by Massachusetts General Hospital, this one is the 71st largest by enrollment of the 77 interventional ones that give a count, is one of 5 that started in 2011, is one of 15 in phase 4, and was the 31st registered.
3,051 studies on the registry are indexed under Depressive Disorder, Major; 596 are open to participants now.
Browse Depressive Disorder, Major studies →9 of the 88 studies in Depressive Disorder, Major by Massachusetts General Hospital are open now, in 1 country. Recruiting first, the newest first:
Massachusetts General Hospital · Sites in United States
Ages 18+
Massachusetts General Hospital · Sites in United States
Ages 18+
Massachusetts General Hospital · Sites in United States
Ages 25–50
Massachusetts General Hospital · Sites in United States
Ages 18–65 · Healthy volunteers
Massachusetts General Hospital · Sites in United States
Ages 18+
By country, each count listing its studies:
Of the 419 Depressive Disorder, Major studies recruiting now, 93 (22%) set no upper age limit and 299 (71%) stop at 75 or younger; 55 take children under 18; 100 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
88 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 15 · Phase 3 5 · Phase 4 15
First in 2001; this study’s year is marked. 5 started in 2011.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 5 is below the median of 80 across 2,535 interventional studies indexed under Depressive Disorder, Major.
Median enrollment 40 across the 77 interventional studies, 70 across the 11 observational. Of the 68 that completed or were terminated, 41 (60%) have results posted.
This tab as a report to print or save as PDF → With an account.
Massachusetts General Hospital is the lead sponsor of 2,591 studies on the registry; 445 are open to participants now.
Of its 224 completed or terminated interventional studies of FDA-regulated products, 168 (75%) have results posted.
6 of the studies in Depressive Disorder, Major by Massachusetts General Hospital that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05767593Massachusetts General HospitalClinical Validation of Samsung Smartwatch | 2026-12-01 |
| NCT07610928Massachusetts General HospitalStress Management and Meditative Movements for Asian Americans With Depression and Physical Symptoms | 2027-03-31 |
| NCT05774665Massachusetts General HospitalSpecialized Pro-resolving Lipid Mediators and Treatment Resistant Depression | 2027-03-31 |
| NCT05450432Massachusetts General HospitalLong-Term Maintenance With Ketamine and Esketamine for Reduction of Suicide in High-Risk Patients With Depression | 2027-05-01 |
| NCT05570812Massachusetts General HospitalNeuroactive Steroid to Treat Depressed Mood: A Trial for People With HIV | 2027-06-30 |
Add all 6 to your calendar (.ics) → With an account.
Among the 88 studies in Depressive Disorder, Major by Massachusetts General Hospital, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to determine the safety and effectiveness of a nutritional supplement, the probiotic bacteria GanedenBC30. Probiotics are live microorganisms which when taken in large enough amounts are supposed to provide a health benefit. The investigators would like to see whether this supplement can be used as a treatment for Irritable Bowel Syndrome (IBS) and Major Depressive Disorder (MDD). Participants in the study will have both IBS and MDD. In order to find out if GanedenBC30 is effective in treating IBS and MDD, the investigators will compare it to a placebo. About 32 people will take part in this research study. About half of these 32 people will take part at Charles River Medical Associates and half will take part at Burlington Medical Associates. Participants will be recruited from among patients already being seen at Charles River Medical Associates or Burlington Medical Associates for their primary care. The study will last for two months, during which time participants will make eight study visits and will take either Ganeden BC30 or placebo. The investigators hypothesize that subjects treated with the probiotic will have significantly better outcomes with regard to depression and IBS symptoms compared to those who receive placebo.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Delirium, dementia, amnestic, or other cognitive disorder; Schizophrenia or other psychotic disorder, based on the PDSQ; Bipolar I or II disorder, based on the PDSQ; Patients with a Axis II () diagnosis of borderline, antisocial, paranoid, schizoid, schizotypal or histrionic personality disorder.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Arm 1 will take GanedenBC30 (Bacillus coagulans GBI-30, 6086, 1 capsule/day) for 60 days.
Drug: Ganeden BC30
Arm 2 will take placebo (sugar pill) for 60 days.
Other: Placebo (sugar pill)
Arm 3 will take placebo (sugar pill) for 30 days, followed by Ganeden BC30 for 30 days.
Other: Ganeden BC30, Placebo (sugar pill)
2 billion CFU per capsule; One pill daily for 60 days
1 pill daily for 60 days
Ganeden BC30 (2 billion CFU per capsule), One capsule daily for 30 days Sugar Pill (placebo), One capsule daily for 30 days
Quick Inventory of Depressive Symptomatology - Self Report (QIDS-SR)
The Quick Inventory of Depressive Symptomatology - Self Report (QIDS-SR)is a self report measure that addresses depressive symptoms. MDD responders will be defined as those exhibiting a 50% decrease in the QIDS SR at study endpoint.
Time frame: Administered at each of 8 study visits (every 10 days), Endpoint is Final Visit
IBS Severity Scoring System (IBS-SSS)
The IBS-SSS is a validated instrument used to assess common IBS symptoms over the past 10 days including abdominal pain, distention, bowel habit, and global function. The IBS-SSS will be used to assess the absolute change in specific IBS symptoms at endpoint, namely the bloating/distension score.
Time frame: Adminsitered at each of 8 study visits (every 10 days), Endpoint is Final Visit
Visual Analog Scale (VAS)
The VAS is a self-administered measure of abdominal pain, discomfort, and bloating. The change in total score from baseline to study endpoint will be assessed.
Time frame: Administered at each of 8 study visits (every 10 days), Endpoint is Final Visit
Adequate Relief of IBS Pain (AR-IBS)
The AR-IBS is a self-administered measure of the adequacy of the relief of IBS pain.
Time frame: Adminstered at each of 8 visits (every 10 days), Endpoint is Final Visit
Patient Global Impression of Change (PGI-C) - IBS Symptoms
The PGI-C is a self-administered measure of the degree of improvement in IBS symptoms compared to the first study visit. Degree of improvement in IBS symptoms from first to final visit will be assessed using this scale.
Time frame: Administered at each of 8 visits (every 10 days), Endpoint is Final Visit
| Milestone | GanedenBC30 | Sugar Pill | Ganeden BC30, Sugar Pill |
|---|---|---|---|
| Started | 1 | 2 | 2 |
| Completed | 0 | 2 | 2 |
| Not completed | 1 | 0 | 0 |
The Quick Inventory of Depressive Symptomatology - Self Report (QIDS-SR)is a self report measure that addresses depressive symptoms. MDD responders will be defined as those exhibiting a 50% decrease in the QIDS SR at study endpoint.
No measurements were reported for this outcome.
The IBS-SSS is a validated instrument used to assess common IBS symptoms over the past 10 days including abdominal pain, distention, bowel habit, and global function. The IBS-SSS will be used to assess the absolute change in specific IBS symptoms at endpoint, namely the bloating/distension score.
No measurements were reported for this outcome.
The VAS is a self-administered measure of abdominal pain, discomfort, and bloating. The change in total score from baseline to study endpoint will be assessed.
No measurements were reported for this outcome.
The AR-IBS is a self-administered measure of the adequacy of the relief of IBS pain.
No measurements were reported for this outcome.
The PGI-C is a self-administered measure of the degree of improvement in IBS symptoms compared to the first study visit. Degree of improvement in IBS symptoms from first to final visit will be assessed using this scale.
No measurements were reported for this outcome.
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo for 60 Days | — | 0/2 (0%) | 0/2 (0%) |
| GanedenBC30 for 60 Days | — | 0/1 (0%) | 1/1 (100%) |
| Placebo for 30 Days, Followed by GanedenBC30 for 30 Days | — | 0/2 (0%) | 1/2 (50%) |
| Event | Placebo for 60 Days | GanedenBC30 for 60 Days | Placebo for 30 Days, Followed by GanedenBC30 for 30 Days |
|---|---|---|---|
| Cerebral infarct; residual leg weakness and face droopingCardiac disorders | 0/2 | 1/1 | 0/2 |
| Labial cyst, constipation, and tension headacheGastrointestinal disorders | 0/2 | 0/1 | 1/2 |
| Sore throatImmune system disorders | 0/2 | 0/1 | 1/2 |
| Sinus infectionInfections and infestations | 0/2 | 0/1 | 1/2 |
| Right flank painMusculoskeletal and connective tissue disorders | 0/2 | 0/1 | 1/2 |
| Age, Categorical(Participants) | GanedenBC30 | Sugar Pill | Ganeden BC30, Sugar Pill | Total |
|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 1 | 2 | 2 | 5 |
| >=65 years | 0 | 0 | 0 | 0 |
| Sex: Female, Male(Participants) | GanedenBC30 | Sugar Pill | Ganeden BC30, Sugar Pill | Total |
|---|---|---|---|---|
| Female | 1 | 2 | 2 | 5 |
| Male | 0 | 0 | 0 | 0 |
| Ethnicity (NIH/OMB)(Participants) | GanedenBC30 | Sugar Pill | Ganeden BC30, Sugar Pill | Total |
|---|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 | 0 |
| Not Hispanic or Latino | 1 | 2 | 2 | 5 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | GanedenBC30 | Sugar Pill | Ganeden BC30, Sugar Pill | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 0 |
| White | 1 | 2 | 2 | 5 |
| More than one race | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Region of Enrollment(participants) | GanedenBC30 | Sugar Pill | Ganeden BC30, Sugar Pill | Total |
|---|---|---|---|---|
| United States | 1 | 2 | 2 | 5 |
The record gives a start of Jun 2011, a primary completion of Feb 2012 and a completion of Feb 2012. It does not say whether these dates are actual or estimated.
Results were first posted in Aug 2013, 1 year 6 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Aug 2013. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Heyndrickxia coagulans
Massachusetts General Hospital →